ReviewClinical pharmacology and therapeutics2026
The Framework of Precision Pharmacotherapy in Metabolic Dysfunction-Associated Steatohepatitis: A Network Meta-Analysis.
Review in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The challenge of precision treatment for metabolic dysfunction-associated steatohepatitis (MASH) is increasingly recognized, for which comparative evidence remains limited. We performed a network meta-analysis of randomized controlled trials (RCTs) to examine the relative efficacy of pharmacotherapies in MASH. RCTs investigating pharmacologic treatments were systematically searched. The primary outcomes were fibrosis improvement of ≥ 1 stage without worsening of MASH and MASH resolution without worsening of fibrosis. Random-effects models were used to calculate the odds ratios (ORs) with 95% confidence interval. About 69 RCTs, including 16,180 patients with MASH, were included. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, thyroid hormone receptor-β (THR-β) agonists, incretins, and fibroblast growth factor-21 (FGF21) analogs were associated with improvements in both primary outcomes compared with placebo. Subgroup analyses suggested that treatment responses may vary across clinically relevant populations, such as those defined by cirrhosis status and type 2 diabetes (T2D). FGF21 analogs were associated with higher odds of MASH resolution in cirrhotic MASH patients compared with placebo (OR = 4.25, 95% CI = 1.97-9.17), whereas incretins showed favorable associations with MASH resolution in MASH patients without cirrhosis (OR 5.92, 95% CI = 3.46-10.15). Compared with placebo, SGLT2 inhibitors were associated with higher odds of fibrosis improvement in MASH patients with T2D (OR = 9.48, 95% CI = 2.43-37.00) as well as in MASH population without T2D (OR = 4.67, 95% CI = 1.30-16.79). Although the depth of subgroup evidence is currently limited, these findings provide a comparative framework to inform future stratified trial design and therapeutic development in MASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.